Evaluating the prognostic and predictive value of the FOLR1 high-like signature and of RFC expression in large prospective cohorts of ovarian cancer patients treated with mirvetuximab soravtansine and novel strategies is warranted. The gene discussed is FOLR1; the disease is ovarian carcinoma.